We shall see, but don't be surprised if I win this bet. We both know VG will need money. As shown in the Form 10, DMBM is almost paid off and may be by now. The last time money was received from DMBM was March 2013, as far as a Convertible Note, so I'm pretty sure borrowing from DMBM is over.
Now where will VG also look for money to fund the future. I think it will come from a partnership and from Big Pharma.
With licensing deals put together with milestone royalties, don't be surprised if it happens.
Notice the last paragraph I copy and paste. 10 million upfront for two pre-clinical programs.
Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms.
Licensing deals have become an important strategy for big pharma companies looking to fill their development pipelines, a strategy that also provides a lifeline to biotech companies as it gives them much-needed cash to keep their business alive. This is often structured as a technology access fee, providing cash up-front, followed by milestone payments to mark successes and royalties on sales if the product ultimately makes it onto the market.
Another important therapeutic area research-wise is respiratory disease. Here, Johnson & Johnson has licensed two advanced small molecule preclinical programmes in asthma and COPD from Sweden’s Orexo, plus another for an undisclosed indication. The initial deal is for three years and Orexo’s research will be funded to the tune of up to $21.5m, $10m of it upfront. It could ultimately be worth more than $550m plus royalties.
With two and a half months left in our double or nothing bet, I still feel a partnership is coming.
The animal studies should be done or almost done and with the uplist coming, it's not a bad time for a partnership if anyone is interested in the VG1177 peptide.
It seems there has been enough success in other peptide work to have hopes.
Here is the company listed in the Form 10 amendment that VGLS is working with and take a look at their recent article. It all promising in the world of peptides!
A biopharmaceutical manufacturer rooted in North Augusta is expanding its workforce and operations to keep pace with an increased market demand.
AmbioPharm Inc., a contract peptide producer for drug companies across the country, is investing $5 million to double its manufacturing operations and boost the staff by about 20 employees by this fall, said Robert Geiger, the company’s vice president of quality.
“Our customers have become more successful, so we’ve become more successful,” said Jim Hampton, the company’s executive vice president of business development. “We have nearly 100 customers in various stages of clinical studies and pre-clinical studies.”
News 
Market Data 
Discover 
AI
